Logo
x

Search

Subscribe Now

zealand pharma

Zealand Pharma and Boehringer Ingelheim Report the US FDA’s Breakthrough Therapy Designation of Survodutide for MASH

Zealand Pharma and Boehringer Ingelheim Report the US FDA’s Breakthrough Therapy Designation of Survodutide for MASH

  • October 8, 2024
Zealand Pharma Submits an NDA for Glepaglutide to the US FDA for the Treatment of Short Bowel Syndrome (SBS)

Zealand Pharma Submits an NDA for Glepaglutide to the US FDA for the Treatment of Short Bowel Syndrome (SBS)

  • December 26, 2023
Zealand Pharma Reports Part 1 Results of Multiple Ascending Dose Trial for ZP8396 for the Management of Overweight and Obesity

Zealand Pharma Reports Part 1 Results of Multiple Ascending Dose Trial for ZP8396 for the Management of Overweight and Obesity

  • July 3, 2023
Zealand Pharma Reports Results from P-Ia Study of ZP8396 for Patients with Obesity and Diabetes

Zealand Pharma Reports Results from P-Ia Study of ZP8396 for Patients with Obesity and Diabetes

  • March 28, 2023
Zealand Pharma Reports P-III (EASE 1) Trial Results of Glepaglutide for the Treatment of Short Bowel Syndrome

Zealand Pharma Reports P-III (EASE 1) Trial Results of Glepaglutide for the Treatment of Short Bowel Syndrome

  • September 30, 2022
Zealand Pharma Report Enrollment Completion in P-III Study of Dasiglucagon in Children with Congenital Hyperinsulinism

Zealand Pharma Report Enrollment Completion in P-III Study of Dasiglucagon in Children with Congenital Hyperinsulinism

  • February 15, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.